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ABSTRACT 
Efficacy studies comparing ECT and tricyclics in depression have had methodological 
limitations. This study compared EC T and imipramine (IMN) prescribed as the first line of treatment 
in major depression, Drug-naive, consenting, DSM-IV major depression patients (n=28), were 
randomized to receive either bilateral ECTs or IMN (225 mg/d) for four weeks. Severity of depression 
was scored at twice weekly intervals. Subjective side effects were scored at second and fourth 
week. Patients had significant reductions in depression scores over time but there were no differences 
between the two treatment groups. The rate of antidepressant response did not significantly differ 
between the two groups. ECT group had significantly fewer side effects. IMN offered therapeutic 
response comparable to ECT without compromising on the speed of antidepressant response, but 
caused more side effects. 
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The antidepressant efficacy of both 
imipramine (IMN) and ECT is undisputed. But 
the most common indication for ECT in 
depression is nonresponse to pharmacotherapy 
(Weiner & Coffey, 1988; APA, 1990). Current 
research on comparative efficacy of ECT and 
antidepressants has focused on drug-resistant 
cases (Dinan & Barry, 1989; Folkertsetal.,1997). 
Abrams (1997) noted that the case for therapeutic 
advantage of ECTs over antidepressant drugs 
rests primarily on three studies (Greenblatt et 
al.,1964; Shepherd,1965; Gangadhar et 
al., 1982). Rifkin (1988) and Abrams (1997) point 
to several methodological inadequacies viz., 
definition of depression, sample size, dose of the 
drugs and statistical analyses. 
Nevertheless, one of the primary 
indications for ECT is when a rapid and definitive 
response is needed (APA, 1990; Abrams, 1997). 
The expected rapidity of response is hence 
important in choosing between antidepressant 
treatment options. The methodological problems 
in studies of the speed of antidepressant 
response were reviewed recently (Muller & 
Moller, 1998; Nobler et al.,1997). Among the 
important suggestions were, use of more 
frequent clinical rating, survival analysis statistics 
etc. This study examined the relative efficacy 
and speed of antidepressant response of ECT 
and IMN in major depressive disorder. 
MATERIAL AND METHOD 
Patients were recruited from the outpatient 
department of the National Institute of Mental 
Health and Neurosciences during a one year 
period on the following criteria: Major Depressive 
Disorder (DSM-IV), drug-naive status for the 
current episode of depression, a total score of 
more than 16 on the 17-item Hamilton's Rating 
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Scale for Depression (HRSD); age between 20 
and 60 years and informed consent to participate 
in study. The patients-were excluded if they had 
systemic or neurological illnesses, substance 
dependence, bipolar affective disorder, psychotic 
disorder, concurrent anticonvulsant drug usage 
or ECT in the past six months. A total of 152 
major depressive disorder patients were 
screened. Diagnosis of the patients was 
independently confirmed using DSM-IV checklist 
by an experienced clinician (BNG). Thirty six 
patients met one or more exclusion criteria and 
84 refused consent. The patients were kept drug 
free except for 'placebo-B complex' tablets in 
the first week. Two patients scored <8 on HRSD 
at the end of this week and were excluded. In 
none of the others (n=30) a reduction of >20% 
on HRSD occurred nor total HRSD became 
lesser than 17 before starting treatment. The 
study sample consisted of 30 patients. The 
patients were equally randomized to eith6r ECT 
or IMN, treatment groups. One patients switched 
to mania during IMN treatment and was dropped. 
A randomly identified patient from the ECT group 
was omitted from the analysis (n=28). Patient 
groups were comparable on the pretreatment 
variables except illness severity (Table 1). 
Modification of the ECT procedure was 
achieved using atropine 0.15 ug/kg, thiopentone 
3 mg/kg and succinylcholine 1 mg/kg in that order 
intravenously. Intermittent positive pressure 
ventilation with 100% oxygen was provided till 
resumption of spontaneous and regular 
breathing. ECT was administered using a 
constant current, bidirectional brief pulse ECT 
device (NIVIQURE). The stimulus parameters 
of the device were as follows : amplitude (800 
mA), pulse width (1.25 msec) and pulse 
frequency (125 pps). The total stimulus dose 
(mC) is adjusted by setting the stimulus train 
length (0.2-3.6s). Standard bifronto-temporal 
stimulus electrode position was used. The 
stimulus threshold was determined by the 
'empirical titration procedure' during the first ECT 
for all the patients. This involved administering 
the stimulus from an initial dose of 30 mC 
upwards in steps. Initial two steps were of 15mC 
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and subsequent steps were of 30 mC. The 
threshold stimulus dose was defined as the dose 
at which a EEG seizure of at least 25 seconds 
duration was obtained. Suprathreshold dose viz., 
60 jnC above threshold, was administered for 
subsequent ECTs. Both motor (right ankle/arm 
cuff) and EEG (F3 & F4 referenced to common 
mastoids) seizures were monitored. ECTs were 
administered twice weekly but reduced to once 
a week if HRSD scores were less than eight for 
a minimum of one week. 
IMN was given orally at bed time in a dose 
of 225 mg/day, from the first day itself except in 
patients older than 50 years (n=4) for whom the 
dose was 150 mg/day. A trained psychiatrist (PM) 
who had randomized the patients was 
responsible for ensuring treatment and care 
during the trial period. 
Assessments were independently carried 
out by a trained rater uninvolved with the treatment 
and without reference to the treatments. All 
assessments were done between 48 and 72 hours 
after the last ECT. The rater had no access to 
clinical records. Assessments included 17-item 
HRSD (Hamilton, 1967), six item subscale of 
HRSD (Bech & Rafaelson, 1986), DSM-IV 
melancholia checklist (APA, 1994), Montgomery-
Asberg Rating Scale (MADRS); (Montgomery & 
Asberg, 1979), Clinical Global Impression (CGI); 
(Guy, 1976) and Beck's depression inventory (BDI); 
(Beck et al.,1961). They were administered at 
pretreatment (baseline/day-0) and twice weekly 
thereafter for four weeks. Patients self-reported 
their improvement (no change to totally recovered) 
on a 100 mm Visual Analog Scale (VAS) twice 
weekly for four weeks after active treatment 
commenced. BDI items were read out and the 
patients responses were recorded on a video 
interview once a week (VBDI). The video records 
were edited for any disclosure of treatment given 
and were coded to mask their order in the 
treatment period. The two independent, trained 
researchers uninvolved in the study rated these 
video records. Side effects were rated at the end 
of two and four weeks using Columbia side effect 
check list (Sackeim et al., 1987). 
Sociodemographic data, pre-treatment 
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illness severity and side effect check list scores 
were compared between the two groups using 
independent sample t-test. Total scores on 
HRSD, BDI and MADRS as well as VAS & CGI 
scores overtime in the two groups were analysed 
using 2-way RMANOVA; pre-treatment total 
HRSD score was used as covariate. Time to 
remission of a symptom was defined by the 
number of days to the earliest assessment 
occasion on which it was rated zero. Between 
group differences in time to remission of 
individual symptoms (except lack of insight & 
loss of weight) of the HRSD were also examined 
using independent sample T test. The two 
treatment groups were also similarly compared 
on a measure of syndromic remission viz., total 
HRSD score <8. Time to remission was analyzed 
by Kaplan-Meier survival analysis. Significance 
(Alfa) was set at 5% level. Intraclass correlation 
was used to examine agreement between video 
BDI and corresponding clinical BDI scores at 
each of the weekly assessments. 
RESULT 
Rates of remission (HRSD<8) in ECT & 
imipramine group were 71 % & 78% respectively. 
The mean scores & SD on the various 
instruments at each of the assessment occasions 
are provided in table 2. 
On 2-way RMANOVA there was a 
significant occasion effect on total scores of 
HRSD (F=35.1; d.f.=208, 8; p<0.001), BDI 
(F=16.2; d.f.=208,8; p0.001) and MADRS (F=66; 
d.f.=208, 8; p<0.001) as well as on VAS (F=8.8; 
d.f.=208, 8; p<0.001); CGI severity (F=41.1; 
d.f.=208, 8; p<0.001) & CGI improvement 
(F=29.7; d.f.=182, 7; p<0.001) scores. However, 
there was no significant group effect : HRSD 
(F=0.07; d.f.=26,1; p<0.7), BDI (F=0.13; d.f.=26, 
1; p=0.6), MADRS (F=0.22; d.f.=26, 1; p=0.7). 
VAS (F=0.36; d.f.=26, 1; p<0.6), CGI severity 
(F=0; d.f.=26, 1; p=0.5) & CGI improvement 
(F=0.24; d.f.=26, 1; p=0.5). There was a 
significant interaction effect: HRSD (F=35.07; 
d.f.=208, 8; p<0.001), BDI (F=16.2; d.f.=208, 8; 
p<0.001), MADRS (F=16.2; d.f.=208, 8; 
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p<0.001), VAS (F=21.4; d.f.=182, 7; pO.001), 
CGI severity (F=41.1; d.f.=208, 8; p<0.001) & 
CGI improvement (F=29.7; d.f. = 182, 7; 
p<0.001). The six-item sub-scale of HRSD 
followed a similar pattern. There was a significant 
occasion effect (F=23.4; d.f.=208, 8; p<0.001) 
without group effect (F=0.17; d.f.=208, 8; p=0.17) 
and interaction effect (F=1.3; d.f.=208, 8; p=0.3). 
All patients could not be interviewed on 
the video due to practical dificulties. Only 21 
patients were interviewed on all four post-
treatment weeks (of whom only 12 had interview 
at pre-treatment). This VBDI data of 21 patients 
was analyzed. There was a good correlation 
between the clinical (PS) and video assessment 
scores (NM); intraclass correlations (ICC) were 
0.72, 0.86, 0.72, 0.81 on post treatment 
occasions 1,2,3 & 4 respectively. Ratings of one 
of the raters (NM) was used for the remaining 
analysis. On 2-way RMANOVA of the VBDI 
scores, there was no group effect (F=0.2; d.f.=16, 
1; p=0.7), however there was a significant, 
occasion effect (F=8.8; d.f.=48,3; p<0.001) and 
interaction effect (F=3.6; d.f.=48, 3; p=0.02). 
Patients with melancholic features (DSM-
IV; n=21) were similarly analysed separately. 
There was a significant occasion effect with 
HRSD (F=24.2; d.f.=152, 8; p<0.001), BDI 
(F=9.5; d.f.=152. 8: p<0.001), MADRS (F=41.7; 
d.f.=152, 8; p<0.001), VAS (F=13.2; d.f.=133, 
7; p<0.001), CGI severity (F=27.2; d.f.=152, 8; 
p<0.001) & CGI improvement (F=27.2; d.f.=133, 
7; p<0.001). There was however no group effect: 
HRSD (F=0.4; d.f =19, 1; p=0.3), BDI (F=0.58; 
d.f.=19, 1; p=0.2), MADRS (F=0.57; d.f.=19, 1; 
p=0.2), VAS (F=0.02; d.f.=19, 1; p=0.7), CGI 
severity (F=0.25; d.f. = 19, 1; p=0.4) & CGI 
improvement (F=0.25; d.f.=19, 1; p=0.2). There 
was no interaction effect: HRSD (F=1.6; 
d.f.=152, 8; p=0.2). BDI (F=2.6; d.f.=152, 8; 
p=0.06), MADRS (F=2.4; d.f.=152, 8; p=0.08), 
VAS (F=1.6; d.f.=152, 8; p=0.2), CGI severity 
(F=2.1; d.f. = 152, 8; p=0.5) and CGI 
improvement (F=0.96; d.f.=152, 8; p=0.5). 
The side effect scores (Columbia scale) 
at week 2 and 4 in the ECT group (6.7±5.2; 
4.9±5.5) were lower than the corresponding 
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TABLE 2 
MEAN (SD) SCORES OF THE TWO GROUPS (ECT & IMN) ON DIFFERENT INSTRUMENTS (MEASURES) 
AT PRE-AND EIGHT POST-TREATMENT OCCASIONS 
Days-
Measure 
HRSD 
MADRS 
BDI 
VAS 
CGIs 
CGIi 
CGIe 
Groups 
ECT 
IMN 
ECT 
IMN 
ECT 
IMN 
ECT 
IMN 
ECT 
IMN 
ECT 
IMN 
ECT 
IMN 
Pre(O) 3 7 10 
28.2(3.9) 21.2(9.2) 15.6(11.2) 9.9(8.3) 
24.7(4.9) 15.6(7.6) 11.4(8.7) 9.5(8.5) 
14 
7.0(7.4) 
7.5(7.4) 
46.8(6.4) 29.0(16.1) 21.7(15.9) 13.5(12.8) 10.2(12.2) 
39.5(6.0) 20.7(13.1) 155(14.1) 11.2(120) 8.8(11.3) 
53.2(12.1)37.3(18.0)32.9(21.2) 22.4(20.7) 17.9(18.8) 
41.8(7.4) 29.7(18.2) 25.9(22 5)16.9(18 1) 
27.9(32.3) 43 2(37.9) 64 7(32.3) 
12.3(14.9) 
17 
6.1(6.8) 
7.5(9.1) 
7.7(9.6) 
10.5(10.7) 
15.1(16.3) 
18.4(21.0) 
72.5(33.4) 765(27.3) 
34.2(36 2) 51.3(43.3) 61.7(43.2) 59.8(38.3) 63 2(40.8) 
5.7(0.7) 4.5(1.6) 3.5(1.8) 2.7(1.6) 
5.4(0.5) 3.6(1.4) 3.2(1.8) 2.7(1.5) 
2.7(0.9) 2.2(0.9) 1.7(0.7) 
2.3(1.0) 2.1(1.0) 1.7(0.8) 
2.0(0.8) 2.3(1.0) 2.9(1.0) 
1.5(1.0) 1.8(1.5) 2.2(1.4) 
2.1(1.3) 
2.2(1.4) 
1.5(0.5) 
1.6(0.7) 
3.1(1.0) 
2.3(1.3) 
2.0(1.2) 
2.5(1.6) 
1.5(0.5) 
1.7(0.7) 
3.0(0.9) 
2.3(1.3) 
21 
5.8(6.2) 
8.2(8.4) 
8.2(10.6) 
24 
4.6(5.7) 
6.0(8.6) 
5.6(6.6) 
10.7(12.4) 6.7(10.9) 
9.8(13.0) 
16.4(17.4) 
8.4(11.1) 
13.1(18.0) 
77.2(27.5) 86.1(21.8) 
72 2(36.8) 64.0(40 9) 
2.1(1.2) 
2.2(1.6) 
1.3(0.4) 
1.7(0.9) 
3.0(0.9) 
2.1(1.3) 
1.6(0.8) 
2.0(1.3) 
1.2(0.5) 
1.5(0.7) 
3.2(0.9) 
2.4(1.2) 
28 
3.8(5.0) 
5.8(8.5) 
4.2(5.8) 
8.2(12.4) 
6.7(8.6) 
12.2(18.3) 
86.2(19.5) 
724(37 7) 
1.5(0.6) 
1.9(1.4) 
1.2(0.4) 
1.3(0.7) 
3.3(0.9) 
2.4(1.2) 
scores in the imipramine group (12.5±10.4; 
9.4±9.5); (p<0.05 on both comparisons). On 2-
way RMANOVA the CGI efficacy index scores 
rose over the 8 post-treatment occasions in both 
treatment groups (F=2.5; d.f.=182, 7; p<0.05) 
but mean scores of the CGI efficacy index were 
significantly higher in the ECT group (F=4.2; 
d.f.=26, 1; p<0.05). 
Survival analysis (Kaplan Meier) showed 
that the time to remission did not show group 
differences: HRSD < 8 (Breslow statistic=0.03; 
d.f. = 1; p=0.8) and CGI improvement < 2 
(Breslow statistic=2.1; d.f.=1; p>0.5). Further 
survival analysis of the number of days taken 
for 50% improvement in the HRSD scores also 
was not different between the two treatment 
groups (Breslow statistics.35; d.f.=1; p=0.24). 
In the HRSD sleep items', only initial 
insomnia (X
2=6.01, p<0.05) & middle insomnia 
(X
2=6.4, p<0.05) scores dropped to zero earlier 
in the imipramine group than in the ECT group. 
Time to remission did not differ between the 
groups with respect to other individual symptoms 
including psychomotor retardation (p>0.05). 
DISCUSSION 
The high remission rates in both ECT and 
imipramine groups (71% & 78% respectively) 
could be because of several factors: 1) The 
patients were natural responders' for any 
somatic therapy as they were never treated for 
the current episode. In contrast, patients who 
failed to respond to medication were less likely 
to respond to subsequent ECTs (Prudic et al., 
1989). 2) Majority of the patients were young 
and in their first episode of depression. With 
recurrent unipolar episodes and older age, 
treatment resistance increases (Avery & 
Lubrano, 1979). 3) Three quarters of patients 
had melancholic features indicating good 
prognosis on Newcastle prognostic scale (Carney 
etal.,1965). 4) Both treatments followed optimal 
standards: twice weekly bilateral ECTs & 
standard doses of imipramine. The response to 
ECT is as expected from earlier reports 
231 C. PANNEER 
(Greenblatt et al.,1964; Shepherd,1965; 
Jagadeesh et al.,1992; Gangadhar et al.,1993). 
The response to imipramine is however better 
than in other prospective controlled trials 
(Greenblatt et al., 1964; Shepherd, 1965). 
Several randomized prospective trials had 
shown that ECT was more effective than tricyclic 
antidepressant drugs (Bruce et al.,1960; Robin 
& Harris, 1962; Fahy et al, 1963; Wilson et al, 
1963; Greenblatt et al.,1964; Shepherd, 1965; 
Gangadhar et al.,1982). The same was not 
replicated in the present study. Out of these one 
study (Gangadhar et al.,1982) was the only 
strictly double blind study. This as well as the 
other studies had methodological pitfalls viz., 
heterogeneous patients population (Robin & 
Harris, 1962; Greenblatt et al.,1964) escalating 
doses of tricyclic antidepressant drug 
(Gangadhar et al.,1982), relatively low doses of 
imipramine (Wilson et al., 1963; Gangadhar et 
al.,1982) and unclear antidepressant status 
(Bruce et al.,1960; Fahy et al.,1963) and sine 
wave ECTs (Greenblatt et al.,1964; Shepherd, 
1965; Gangadhar et al.,1982). 
The study limited the role of 'placebo' 
response. Patients were recruited into the study 
only after confirming that they showed no placebo 
response to B-complex tablets during one week 
ofobservationintheward. Placebo response was 
also less likely as three quarters of the patients 
had melancholic features. Also, separate analysis 
of patients with melancholic features did not detect 
between group differences. An early improvement 
of sleep and anxiety symptoms might give a 
spurious advantage to tricyclic antidepressant 
drug. Bech and Refaelson (1986) have identified 
six items of HRSD which represent the core 
depression' syndrome. The reduction of scores 
on this sub-scale can be regarded as a 'true 
antidepressant' effect. Comparison on this sub-
scale too detected no group differences. The 
scores on MADRS which is more sensitive in 
detecting changes in depression also were not 
different in the two groups. 
Although the study design did not follow 
the standard methodology of double blindedness, 
'blind' ratings' was however ensured by the 
SELVAN et al. 
following: The rater did not have access to the 
clinical case records of the patient. Since the 
rating was carried out 48-72 hours after the last 
ECT session, the treatment identification by the 
rater was minimized. It is nevertheless 
recognized that the differential side effect profile 
(greater anticholinergic & sedative profile) of 
imipramine may have betrayed treatment 
identity and influenced HRSD ratings. VBDI was 
available at weekly intervals for most patients 
(n=21). The videos were edited to eliminate 
identification of both treatment status (rater 
blindedness was ensured) and occasion of 
assessment (order effect was excluded). It is 
arguable that differences between the groups 
were missed (Type II error) in the present study. 
Though the mean scores at baseline were higher 
in ECT group RMANOVA statistic took into 
account this difference. These methodological 
considerations were taken to confirm that the 
two treatments do not differ in either remission 
rate or time course of response. 
The speed of remission with ECT was 
comparable to previous studies (Post et al., 1987; 
Rodger etal., 1994; Segman et al., 199-5). These 
studies did not compare the speed of response 
of ECT to tricyclic antidepressant drug. Likewise, 
the speed of remission with imipramine is 
comparable to that reported by (Pollock et al., 
1989; Malhotra & Santosh,1996) who was also 
used a relatively high initial antidepressant dose. 
The present study is the first prospective 
randomized comparison of ECT and imipramine 
with special reference to time to remission. The 
survival analysis found no difference in time to 
syndromic remission between ECT and 
imipramine. One of the reasons for this could 
have been that twice weekly ECTs in contrast to 
thrice weekly ECTs were administered. In 
prospective randomized designs the therapeutic 
advantages of thrice weekly ECTs over twice 
weekly ECTs has not been established 
unequiyocally (McAllister et al., 1987; Gangadhar 
et al.,1993; Lerer et al.,1995). However there 
was an indication in one of the studies (Lerer et 
al., 1995) that speed of antidepressant response 
was faster in the thrice compared to twice weekly 
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ECTs. Contrastingly (Jagadeesh et al.,1992) 
suggested that the response to ECTs is time 
dependent and independent of the frequency of 
ECTs. In this context it is difficult to exclude the 
possibility that the lack of differences observed 
in this study are attributable to ECT frequency. 
Yet another reason for a lack of advantage 
to ECT was that illness severity was lesser in 
the IMN than in the ECT group. In support to 
this argument, reported that a majority of tricyclic 
responders did so by the first week and 
responders were clinically less depressed 
relative to non-responders. 
Do the two treatments differ with respect 
to individual symptom remission? As expected, 
the imipramine group achieved faster remission 
of sleep and psychic anxiety symptoms. Contrary 
to expectation (Browning & Cohen, 1984; Hickey 
et al.,1996), however, psychomotor retardation 
responded at comparable speed in the two 
treatment groups. It is notable that ECT was 
superior on none of the symptoms. 
Imipramine group had more adverse 
effects in comparison to ECT. This could be 
explained as tricyclics at high doses could 
produce greater anticholinergic side effects. The 
finding support previous observations that 
subjective side effect is greater with imipramine 
(Gangadhar et al.,1982). Interstingly, no patient 
developed a life threatening complication or 
TABLE 1 
CLINICAL AND SOCIO-DEMOGRAPHIC DATA OF 
PATIENTS 
Variables 
Age(years)* 
Sex(Male: Female) 
Mamed:Never married 
Years of Education* 
Melancholia(Yes:No) 
Episode duration(weeks)* 
First: Recurrent episode 
Family history(Yes:No) 
Pretreatment HRSD 
Pretreatment CGI severity 
ECT(n=14) 
37.5(9.4) 
7:7 
12:2 
5.1(6.3) 
11:3 
15.4(12.2) 
7:7 
2:12 
28.21(3.92) 
5.78(0.69) 
IMN(n=14) 
42.4(12.1) 
10:4 
14:0 
5.4(5.4) 
10:4 
20.3(11.9) 
11:3 
3:11 
24.71(4.96) 
5.42(0.51) 
Cell contents refer to number of patients. In other cells* it refers 
to mean(SD). The two groups did not differ on any of the 
demographic and clinical variables except pretreatment 
HRSD(t=2.07, p=0.05) 
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intolerance necessitating discontinuation from 
the study despite high dose from the outset. Side 
effect assessments such as cardiac assessment 
and objective .memory scales were not 
administered in the study protocol. This is a 
limitation of this study. To compensate, a global 
measure of therapeutic and side effects 
interaction, CGI efficacy index was used. The 
efficacy index measures the side effect and 
therapeutic responses along two axes. The 
composite score of their interaction is obtained 
at each assessment point. Efficacy index was 
higher in the ECT group at all time points. This 
was expected as the side effect profile was worse 
in the imipramine group compared to ECT group 
and as no therapeutic differences between the 
two groups were noted. This brings forth the 
question : has ECT a place as a first line 
antidepressant treatment? The answer is yes as 
the therapeutic to adverse effect ratio was higher 
with ECT than IMN. 
There is a need to assess the long term 
effects of these two modalities by means of short 
terms & long term follow up of the study cohort. 
The study could be extended to include bipolar 
depressives, psychotic depressive & elderly 
depressed individuals. 
This study produced an unique challenge 
because it is difficult to recruit drug naive cases 
of the depression and subject them to receive 
ECTs as a first line of treatment given the 
established practice of antidepressant drug 
treatment every depressed patient would 
invariably obtain. The study findings must be 
viewed against this background as it provides 
an oppotunity to reassess an issue that ECT 
could be as effective and never inferior to a 
course of antidepressants in major depressive 
disorders and it is unwise not to administer ECT 
until the patient has not responded to 
antidepressant drugs. 
In conclusion, first, both treatment groups 
showed a high remission rate although no treatment 
was superior to the other in therapeutic response. 
Second, time course of response was similar in 
both ECT and imipramine groups. Third, no 
symptom improved faster with ECT. Fourth, in view 
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of better efficacy of ECT compared to imipramine Dinan, T.G. & Barry, S.(1989) A 
the role of ECT as the first line of management of comparison of electroconvulsive therapy with a 
depression merits further attention. combined lithium and tricyclic combination in 
depressed tricyclic nonresponders. Acta 
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